As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth

US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials

 
• By Dave Wallace

With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.

Waves Beach Horizon Sunset
As Amgen’s current biosimilars portfolio recedes, bigger opportunities are on the horizon in the next wave • Source: Shutterstock

More from Biosimilars

More from Products